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Abstract: We have developed a novel cell-based protein-protein interaction assay method. The method relies on conver-
sion of an inactive permuted luciferase containing a Tobacco Etch Virus protease (TEV) cleavage sequence fused onto 
protein (A) to an active luciferase upon interaction and cleavage by another protein (B) fused with the TEV protease. We 
demonstrate assay applicability for ligand-induced protein-protein interactions including G-protein coupled receptors, re-
ceptor tyrosine kinases and nuclear hormone receptors.  
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INTRODUCTION 
  A variety of mammalian cell based protein-protein inter-
action methods have been developed. The methods include 
imaging interaction of fluorescence proteins [1], fluores-
cence or bioluminescence resonance energy transfer [2,3], 
protein-fragment or enzyme-fragment complementation [4-
7], and interaction-induced transcriptional activated reporters 
[8]. Here we describe a novel method based on an inactive 
permuted protein which can be activated by a protease to 
generate stable and sensitive signals for monitoring protein-
protein interactions in mammalian cells. The basic protein-
protein interaction assay design consists of two components: 
an inactive permuted luciferase containing a Tobacco Etch 
Virus (TEV) protease cleavage sequence fused to protein A, 
and protein B fused to the protease TEV [9]. Upon interac-
tion between protein A and B, inactive permuted luciferase is 
cleaved and active luciferase is reconstituted. The luciferase 
signals should be specific and sensitive for specified protein 
A and B interaction. We named this cell-based protein-
protein interaction method as LinkLight assay technology, 
meaning light is generated upon protein A interacting with 
protein B (Fig. 1a). The LinkLight assay does not involve 
transcription and translation, does not need long exposure 
times with compounds, and therefore, has reduced off-target 
signals. The LinkLight assay is different from biolumines-
cence resonance energy transfer (BRET) and fluorescence 
resonance energy transfer (FRET) assays which depend on 
the degree of the spectral overlap, the relative orientation, 
and the distance between the donor and acceptor. The 
method is also different from protein-fragment complemen-
tation assays (PCA) or enzyme-fragment complementation 
assays (ECA) in which fragment spontaneous self-
complementation could produce high background signals, 
especially when the proteins are over-expressed and the two 
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fragments have high complementation affinity. Based on the 
assay principal, the method described here should generate 
stable signals for both transient and stable protein-protein 
interactions. 
MATERIALS AND METHODOLOGIES 
Plasmid Construction 
 Human G-protein coupled receptor (GPCR) DNA frag-
ments without stop codon were generated by polymerase 
chain reaction (PCR) for subsequent subcloning. A flexible 
peptide sequence (G4S)3 was used to link GPCR and TEV 
protease. The tobacco TEV fragment contain 240 amino acid 
sequence was obtained by PCR using tobacco etch virus 
DNA clone (ATCC # 45035) as the template. PCR primers: 
CTCGAGGGAGAAAGCTTGTTTAAGGGAC (5’ primer) 
and GGGCCCCTATTGCGAGTACACCAATTCATTC   
(3’ primer) contain introduced Xho I and Apa I restriction 
enzyme sites to facilitate cloning. GPCR-TEV fusion genes 
were then subcloned into the pcDNA3.1-zero or –hyg vector. 
Firefly luciferase DNA fragments corresponding to amino 
acid sequence 2 to 233 and 234 to 550 were generated by 
PCR using pCRE-Luc (GeneBank accession: AF053461.1) 
as the template and high-fidelity DNA polymerase (Invitro-
gen). An inactive permuted luciferase (pLuc) was con-
structed by using a TEV protease cleavage sequence encod-
ing ENLYFQR was used as a linker to link the C luciferase 
fragment containing amino acids 234 to 550 in front of N 
fragment containing amino acids 2 to 233. The permuted 
luciferase was then fused to the C-terminus of -arrestin 2 
and subcloned into the pcDNA 3.1 vector (Invitrogen). Simi-
larly, nuclear hormone receptor (NHR)-TEV and receptor 
tyrosine kinase (RTK)-TEV constructs were generated by 
replacing GPCR DNA fragment in the GPCR-TEV construct 
with either NHR or RTK DNA fragments by standard mo-
lecular cloning method. NCOA1-pLuc was constructed by 
replacing  -arrestin 2 DNA fragment in -arrestin 2-pLuc 
construct with DNAs encoding NCOA1 nuclear localization 
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to 760. PTB-pLuc was constructed by fusing DNA fragment 
encoding PTB domain of Src homology 2 domain containing 
transforming protein 1 (SHC1) in front of permuted   
luciferase sequence. All constructs were verified by DNA 
sequencing.  
Stable Cell Line Generation 
  CHO, HEK293, and U-2 OS cells were routinely main-
tained and passaged in standard recommended medium with 
Pen/Strep (Invitrogen). Monoclonal cell lines stably express-
ing -arrestin-permuted luciferase fusion protein (HEK__-
arr2-pLuc and U2OS__-arr2-pLuc) were selected with 
G418 250 μg/ml for HEK293 cells or Hygromycin B 500 
μg/ml for U2OS cells. Monoclonal U2OS_PTB-pLuc and 
U2OS_NCOA1-pLuc were selected with Hygromycin B 500 
μg/ml. 
Chemicals 
  All the chemicals were purchased from Sigma-Aldrich 
(USA) and Tocris Biosciences. 
LinkLight Assay 
  Cells stably expressing or transiently expressing GPCR-
TEV and -arr2-pLuc genes were plated into a 384-well 
opaque assay plate (Becton Dickinson) at 10,000 cells per 
well. Cells were incubated overnight, and the culture me-
dium was replaced with serum-free medium and compounds 
were added into the wells. Compounds were added typically 
as dilutions into the culture medium from 10 mM DMSO 
stocks. After 90 min incubation equal volume of Bright-Glo 
luciferase detection reagent (Promega) or BrightLite (Perkin 
Elmer) detection reagent was then added to the wells and 
relative luminescence units (RLU) were recorded on either 
an EnVision or a TopCount plate reader (Perkin Elmer). Al-
ternatively, after 90 min compound incubation, the culture 
medium was removed, and 15 μl of detection reagent was 
added to each well, then relative luminescent signals were 
recorded.  
Cyclic AMP and CRE-Luc Assays 
 PathHunter
TM cAMP kit (DiscoverX) was used in the 
cAMP assay. The assay was performed according to the 
manufacture’s instruction. For CRE-Luc assay, CHO cells 
stably expressing CRE-luciferase reporter gene were trans-
fected with ADRB2-TEV construct and plated in 384-well 
plates. After 24 hour culture, the cells were treated with dif-
ferent concentrations of isoproterenol for 6 hours, and equal 
volume of Bright-Glo was added to each well and RLUs 
were recorded on an EnVision plate reader. 
Flouorometric Imaging Plate Reader (FLIPR) Assay 
  HEK293 cells containing G protein G16 were seeded in 
384-well plates with 10,000 cells per well and were trans-
fected with GPCR-TEV constructs for 24 hours. Cells were 
then loaded with a calcium-sensitive fluorescent dye (FLIPR 
Calcium 3 assay kit, Molecular Devices). After 90 min incu-
bation, compound was added to each well, and fluorescence 
signals were recorded on Fluorometric Imaging Plate Reader 
384 (Molecular Devices). 
RESULTS AND DISCUSSION 
  G-protein coupled receptor and -arrestin interactions 
have been well documented [10, 11]. Biased ligands that 
selectively activate or inhibit G-protein vs. -arrestin signal-
ing pathways can have therapeutic benefits [12]. We used the 
GPCR-arrestin interaction as the model system for GPCR 
LinkLight assay development (Fig. 1b). Inactive permuted 
luciferase (pLuc) was created by breaking the firefly lu-
ciferase coding region into two fragments, re-arranging the 
original fragment order, and re-connecting the fragments 
with a TEV protease cleavage site. The resulting permuted 
luciferase has no enzymatic activity. One particular inactive 
permuted luciferase was created by placing the firefly lu-
ciferase amino acid sequence 234 to 550 (C-fragment) in 
front of the amino acid sequence 2 to 233 (N-fragment). We 
chose the TEV cleavage sequence, ENLYFQR, for inclusion 
in the permuted luciferase gene construct. We evaluated two 
approaches for the assay development. First, we constructed 
ADRB2-TEV plasmid by fusing the TEV protease at the C-
terminal of 2 adrenergic receptor (ADRB2) and con-
structed  -arr2-pLuc plasmid by fusing the permuted lu-
ciferase (pLuc) at the C-terminal of beta-arrestin-2 (-arr2). 
Second, we switched the fusion protein tags of the first de-
sign by fusing -arrestin-2 with TEV and -arrestin-2 with 
the pLuc. Transient expression of two sets of ADRB2 and -
arrestin-2 fusion gene constructs in HEK293 cells produced 
agonist isoproterenol-induced luciferase signals. Clearly, the 
first approach, in which ADRB2 tagged with TEV (ADRB2-
TEV) and -arrestin-2 tagged with the permuted luciferase 
(-arr2-pLuc), exhibited the stronger signal and greater dy-
namic range (Fig. 1c). We speculate that the cytoplasmic 
environment, rather than proximity to the membrane is more 
favorable for the cleaved permuted luciferase fragments to 
reconstitute active luciferase. As a negative control, we co-
transfected cells with -arr2-pLuc and ADRB2 without TEV 
fusion protein constructs, no luciferase signals were ob-
served. We then generated HEK293 cells stably expressing 
ADRB2-TEV and -arr2-pLuc genes. The stable cells pro-
duced much larger signal dynamic ranges since we chose a 
stable -arr2-pLuc reporter line with a low basal level signal 
while having high ligand-induced signal. Antagonist activity 
blocking agonist-induced signals can be easily detected. In 
addition, ligand sphingosine-1-phosphate for the endogenous 
S1P1 receptor in the HEK293 host cells did not produce de-
tectable signals (Fig. 1d), indicating that the endogenous 
receptor and its ligand did not interfere with the assay. Since 
class-A rhodopsin GPCRs can be divided into two subtypes 
based on -arrestin-2 recruitment and receptor desensitiza-
tion, we next evaluated the vasopressin V2 receptor (V2R) in 
the assay development. V2R, unlike ADRB2, which is a type 
A receptor that undergoes fast desensitization and dissociates 
from -arrestin at the plasma membrane, is a type B receptor 
that slowly desensitizes and internalizes to endosomes with 
-arrestins [13]. HEK cells with co-stable expression of 
V2R-TEV and -arr2-pLuc genes produced dose-dependent 
signals in response to agonist arg
8-vasopressin (Fig. 1e), in-
dicating that the GPCR beta-arrestin interaction assay can be 
applied to both type A and type B receptors.  
  To ascertain whether the protein interactions detected in 
GPCR LinkLight assay represented biologically functional 
interactions, we investigated G-protein signaling with the 
TEV tagged GPCRs. We performed cAMP assays in 
HEK293 cells stably expressing ADRB2-TEV and -arr2-
pLuc with an array of ligands. The results of the cAMP assay 
(Fig. 1f) were comparable to the LinkLight assay results. 124    Current Chemical Genomics, 2011, Volume 5  Eishingdrelo et al. 
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Fig. (1). GPCR LinkLight assay. a, The design of LinkLight assay technology. b, A schematic draw of GPCR-TEV and -arrestin-pLuc in-
teraction LinkLight assay. Molecules trigger the interaction of GPCR-TEV fusion protein and -arrestin-pLuc fusion protein, resulting in the 
cleavage of the inactive permuted luciferase and reconstitution of an active luciferase. c, GPCR LinkLight assay with two different designs. 
ADRB2-TEV and Arr2-pLuc plasmids or Arr2-TEV and ADRB2-pLuc-V plasmids were co-expressed transiently in HEK293 cells to pro-
duce ligand-induced luciferase signals. d, Dose response curves of ligands in HEK293 cells stably expressing ADRB2-TEV and Arr2-pLuc 
fusion proteins. e, HEK293 cells stably expressing V2R-TEV and Arr2-pLuc-V fusion proteins and their response to the V2 agonist, Arg8-
vasopressin. f, cAMP assay using HEK293 cells transiently expressing ADRB2-TEV fusion gene in response to agonists, partial agonists, and 
antagonists. g, Cre-Luc assay using CHO cells stably expressing CRE-Luc and transiently expressing ADRB2-TEV genes in response to iso-
proterenol. h, FLIPR assay using HEK293 cells stably expressing Ga16 and transiently expressing ADRB2-TEV genes in response to isopro-
terenol. All curves were generated by using GraphPad Prism 5 software. Data points are represented as mean  SD from n=3. EC50 values 
were derived from non-linear regression with the best-fit equation. 
ADRB2 is Gs coupled receptor and increases cAMP levels in 
response to agonist stimulation. CHO cells containing a 
CRE-Luc reporter gene were transiently transfected with the 
ADRB2-TEV fusion protein construct. We observed ligand-
induced CRE-Luc reporter signals (Fig. 1g). Again, TEV 
tagged GPCR did not alter the G-protein signals. In addition, 
when HEK293 cells containing a promiscuous G16 protein 
transiently expressed the ADRB2-TEV fusion protein, 
ligand-induced Ca
2+ mobilization signals were observed in 
the FLIPR assay. The experiment yielded the expected EC50 
values (Fig. 1h). The results indicate that the GPCR-TEV 
fusion protein does not interfere with G-protein signaling. 
The EC50 values of the four different assay formats tested 
using the ADRB2-TEV construct are summarized in Table 1. 
  To assess general applicability of the conceptual assay 
design for other protein-protein interactions, we investigated 
nuclear hormone receptor (NHR) LinkLight assays (Fig. 2a). 
Once activated, nuclear hormone receptors translocate into 
the nucleus and interact with nuclear receptor co-activator-1 
(NCOA1) to form the transcriptional complex [14]. We 
tagged retinoid X receptor  (RXR) with TEV at the C-
terminal (RXR-TEV) and fused a nuclear hormone interac-
tion domain of NCOA1 with the permuted luciferase 
(NCOA1-pLuc). We expected that active luciferase signals 
would be generated once RXR-TEV and NCOA1-pLuc 
fusion protein make contact in the nucleus. In order to test 
this, we generated U2OS cells stably expressing NCOA1-
pLuc and designated these as U2OS_NCOA1-pLuc cells. 
When U2OS_NCOA1-pLuc cells were transiently express-
ing RXR-TEV, dose-dependent luciferase signals were 
observed (Fig. 2b), indicating retinoic acid-induced 
RXRV and NCOA1-pLuc complex formation and re-
constitution of active luciferase resulted in permuted lu-
ciferase cleavage by TEV. Nuclear hormone receptors are 
classified into multiple subfamilies according their mecha-
nism of action and subcellular distribution in the absence of 
ligand. RXR belongs to subfamily II. We next selected 
estrogen receptor  (ER), a member of subfamily III and 
pregnane X receptor (PXR) for further validation of NHR 
Table  1.  Comparison of EC50 Values of Four Different Assay Formats. The ADRB2-TEV Construct was Used in LinkLight, 
cAMP, FLIPR, and CRE-Luc Assays. GraphPad Prism 5 was Used to Plot all the Data and EC50 Values were Derived 
from Non-Linear Regression with the Best-Fit Equation 
  LinkLight Assay  cAMP Assay  FLIPR Assay  CRE-Luc Assay 
EC50 (Isoproterenol)  3.72e-009 3.07e-009 1.65e-009 2.0e-009 
Hill Slope  1.260 1.552  0.4067  0.9552 126    Current Chemical Genomics, 2011, Volume 5  Eishingdrelo et al. 
LinkLight assay. When U2OS_NCOA1-pLuc cells tran-
siently expressed ER-TEV or PXR-TEV, ligand-induced 
luciferase signals were observed (Fig. 2c and 2d). The re-
sults indicated that NHR LinkLight assay technology can be 
used for broad range of nuclear hormone receptors.  
  Next, we applied LinkLight assay technology to receptor 
tyrosine kinases (Fig. 3a). Once activated, receptor tyrosine 
kinases (RTK) recruit Src homology 2 (SH2) and phosphoty-
rosine binding (PTB) domain containing proteins to initiate 
signal transduction pathways [15]. We used insulin receptor 
as a model for the RTK LinkLight assay development. We 
tagged insulin receptor (INSR) with TEV protein and fused a 
PTB domain with the permuted luciferase. We generated 
U2OS cells stably expressing PTB-pLuc fusion protein. The 
cells were then transiently transduced with the INSR-TEV 
fusion protein and treated with insulin. A dose-dependent 
EC50 curve was generated (Fig. 3b) after adding luciferin, 
indicating insulin-induced interaction between INSR-TEV 
and PTB-pLuc fusion proteins and active luciferase genera-
tion. We then built other receptor tyrosine kinases in the 
RTK LinkLight assay. Epidermal growth factor receptor 
ERBB4 binds ligands such as neuregulin-2 (NRG2) with 
high affinity and stimulates the receptor tyrosine kinase ac-
tivity. We constructed ERBB4-TEV expression vectors. 
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Fig. (2). NHR LinkLight Assay. a, A schematic drawing of NHR-TEV and NCOA1-pLuc interaction LinkLight assay. b, U-2 OS cells stably 
expressing NCOA1-pLuc and transiently expressing RXR-TEV genes showed dose-response curve in response to the ligand retinoic acid. 
c, U-2 OS cells stably expressing NCOA1-pLuc and transiently expressing ER-TEV genes showed dose-response curve in response to the 
ligand -estradiol. d, U-2 OS cells stably expressing NCOA1-pLuc and transiently expressing PXR-TEV genes showed dose-response curves 
in response to the ligand rifampicin. Data points are represented as mean  SD from n=3. EC50 values were derived from non-linear regres-
sion with the best-fit equation. 
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Transient expression of ERBB4-TEV in U2OS_PTB-pLuc 
cells showed ligand-induced signals (Fig. 3c).  
  The reconstituted luciferase activity is generally less than 
10% of the wild type firefly luciferase activity when equal 
amounts are expressed in cells. The reduced activity could be 
due to a less favorable conformation of reconstituted lu-
ciferase or partially cleaved permuted luciferase. Since bio-
luminescent signals are easily detectable, we can read highly 
sensitive luminescent signals from reconstituted luciferase 
without over-expressing fusion proteins. Potentially, other 
commonly used enzymes and fluorescent proteins in reporter 
gene assays could replace the firefly luciferase by permuta-
tion.  
CONCLUSION 
  We report here a novel cell-based assay that can be used 
to measure protein-protein interactions. The assay method is 
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Fig. (3). RTK LinkLight Assay. a, A schematic drawing of RTK-TEV and PTB-pLuc interaction LinkLight assay. b, U-2 OS cells stably 
expressing PTB-pLuc and transiently expressing INSR-TEV genes showed dose-response curve in response to the ligand insulin. c, U-2 OS 
cells stably expressing PTB-pLuc and transiently expressing ErbB4-TEV genes showed dose-response curves in response to the ligand 
NRG2. Data points are represented as mean  SD from n=3. EC50 values were derived from non-linear regression with the best-fit equation. 128    Current Chemical Genomics, 2011, Volume 5  Eishingdrelo et al. 
highly specific, and can be used to assess specific signal 
pathways. Use of full-length proteins in cell-based assays 
offers biologically relevant functional readouts, therefore 
provides better opportunities to identify lead compounds. 
Given the simplicity, flexibility, sensitivity and the low cost 
of the assay, we believe the method can be broadly applica-
ble for many other types of protein-protein interactions. Po-
tentially, many new protein-protein interaction drug targets 
can be explored using LinkLight assay technology offering 
new drug discovery opportunities. In addition, the LinkLight 
assay can replace some currently used tedious assay methods 
and address assay enabling issues for some difficult or in-
tractable drug targets. Furthermore, a new signal pathway 
assay method can provide opportunities to identify new 
chemical matters for old targets. 
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